Radiomics and radiogenomics of prostate cancer
https://doi.org/10.25789/YMJ.2021.73.27
Abstract
This literature review looks at a new emerging field of radiomics, using prostate cancer as an example, to extract high-throughput data from quantitative image characteristics and then combine this information with clinical data, providing prognostic information only on the characteristics of images, and radiogenomics, which compares the obtained features of images with genomic data. The purpose of this review is to provide an update on the application of radiomics-based approaches and to discuss the potential role of radiogenomics in prostate cancer, which will further work out new biomarkers for diagnosis, prognosis and assessment of treatment response and to obtain positive treatment outcomes in patients with prostate cancer.
About the Authors
M. V. Loginova
Republic Clinical Oncological Hospital;
Bashkir State Medical University
Russian Federation
Russian Federation
Loginova Maria Vladislavovna - oncologist of the Oncology Department of Anticancer Drug Therapy;
postgraduate student of the Department of Urology
450054 Ufa, Prospekt Oktyabrya, 73/1
AuthorID: 1016837
contact phone - 8 (937) 1661408
V. N. Pavlov
Bashkir State Medical University of the Ministry of Health of Russia
Russian Federation
Russian Federation
Pavlov Valentin Nikolaevich - Doctor of Medical Sciences, Professor, Corresponding Member the Russian Academy of Sciences, director
Head of Department of Urology with a course IDPO
450008, Republic of Bashkortostan, Ufa, Lenina 3
I. R. Gilyazova
Ufa Federal Research Center of the Russian Academy of Sciences
Russian Federation
Russian Federation
Gilyazova Irina Rishatovna - Candidate of Biological Sciences, docent of the Department of Medical Genetics and Fundamental Medicine, Senior Researcher
450098, Republic of Bashkortostan
Ufa, Davletkildeeva boulevard 5/2
References
1. Clinical guidelines. Prostate cancer: standards of patient management for doctors / ed. Council: All-Russian National Union "Association of Oncologists of Russia" and others - Moscow, 2020. - Access mode: https://oncology-association.ru/files/clinical-guidelines-2020/rak_predstatelnoj_zhelezy.pdf.(In Russ.).
2. Ognerubov N.A. Radiogenomics and radiomics in the diagnosis of malignant tumors: a literature review/ Ognerubov N.A., Shatov I.A., Shatov A.V. // Bulletin of the Tambov University. Series Natural and technical sciences. 2017; 22(6):1453-1460.(In Russ.). Doi: 10.20310/1810-0198-2017-22-6-1453-1460.
3. Ageing populations: the challenges ahead / K Christensen, G Doblhammer, R Rau, et al. // Lancet. – 2009. – Vol.374(9696). - P.1196–208. Doi:10.1016/S0140-6736(09)61460-4.
4. A prostate cancer susceptibility allele at 6q22 increases RFX6 expression by modulating HOXB13 chromatin binding / Q Huang, T Whitington, P Gao, et al. // Nat Genet. - 2014. – Vol.46. – P. 126–135. Doi: 10.1038/ng.2862.
5. Confirmation of the HOXB13 G84E germline mutation in familial prostate cancer / JP Breyer, TG Avritt, KM McReynolds, et al. // Cancer Epidemiol Biomarkers Prev. - 2012. – Vol. 21. – P. 1348–1353. Doi: 10.1158/1055-9965.EPI-12-0495.
6. Do African-American men need separate prostate cancer screening guidelines? / D Shenoy, S Packianathan, AM Chen, et al. // BMC Urol. - 2016. – Vol. 16. P. 19-27. Doi: 10.1186/s12894-016-0137-7.
7. El Bahassi, M. Next-generation sequencing technologies: breaking the sound barrier of human genetics / M. el Bahassi, P.J. Stambrook // Mutagenesis. – 2014. – Vol.29(5). – P.303–310. Doi: 10.1093/mutage/geu031.
8. Environmental and heritable factors in the causation of cancer— analyses of cohorts of twins from Sweden, Denmark, and Finland / P Lichtenstein, NV Holm, PK Verkasalo, et al // N Engl J Med. - 2000. – Vol.343. – P. 78–85. Doi: 10.1136/thoraxjnl-2015-207921.
9. Exome sequencing of African-American prostate cancer reveals loss-of-function ERF mutations / FW Huang, JM Mosquera, A Garofalo, et al. // Cancer Discov. - 2017. – Vol. 7. – P. 973–983. Doi: 10.1158/2159-8290.CD16-0960.
10. Genomic hallmarks of localized, non-indolent prostate cancer / M Fraser, VY Sabelnykova, TN Yamaguchi, et al. // Nature. - 2017. – Vol. 541. – P. 359–364. Doi: 10.1038/nature20788.
11. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24 / M Yeager, N Orr, RB Hayes, et al // Nat Genet. - 2007. – Vol. 39. – P. 645–649. Doi: 10.1038/ng2022.
12. Guideline for the management of clinically localized prostate cancer: 2007 update / I Thompson, JB Thrasher, G Aus, et al. - J Urol. – 2007. – Vol. 177(6). – P.2106–2131. Doi: 10.1016/j.juro.2007.03.003.
13. Health care costs for state transition models in prostate cancer / MD Krahn, KE Bremner, B Zagorski, et al. // Med Decis Making. – 2014. – Vol.34(3). – P.366–78. Doi: 10.1177/0272989X13493970.
14. Inherited DNA-repair gene mutations in men with metastatic prostate cancer / CC Pritchard, J Mateo, MF Walsh, et al. // N Engl J Med. - 2016. – Vol.375. – P. 443–453. Doi: 10.1056/NEJMoa1603144.
15. Integrative genomic profiling of human prostate cancer / BS Taylor, N Schultz, H Hieronymus, et al. // Cancer Cell. - 2010. – Vol. 18. P. 11–22. Doi: 10.1016/j.ccr.2010.05.026.
16. Integrative clinical genomics of advanced prostate cancer / D Robinson, EM Van Allen, YM Wu, et al. // Cell. - 2015. – Vol. 162. – P. 454 - 462. Doi: 10.1016/j.cell.2015.05.001.
17. MAPS: a quantitative radiomics approach for prostate cancer detection / A Cameron, F Khalvati, MA Haider, et al. // IEEE Trans Biomed Eng. - 2016. – Vol. 63(6). – P.1145–1156. Doi: 10.1109/TBME.2015.2485779.
18. Mazurowski, M.A. Radiogenomics: what it is and why it is important / M.A. Mazurowski // J Am Coll Radiol. – 2015. – Vol. 12(8). –P.862–866. Doi: 10.1016/j.jacr.2015.04.019.
19. Parametric shape modeling using deformable superellipses for prostate segmentation / L Gong, SD Pathak, DR Haynor, et al. // IEEE Trans Med Imaging. - 2004. – Vol. 23(3). – P.340–349. Doi: 10.1109/TMI.2004.824237.
20. PI-RADS prostate imaging–reporting and data system: 2015, version 2 / JC Weinreb, JO Barentsz, PL Choyke, et al. // Eur Urol. - 2016. – Vol. 69(1). – P.16–40. Doi: 10.1016/j.eururo.2015.08.052.
21. Prevalence of incidental prostate cancer: A systematic review of autopsy studies / KJ Bell, C Del Mar, G Wright, et al // Int J Cancer. – 2015. – Vol.137(7). – P.1749–57. Doi: 10.1002/ijc. 29538.
22. Prostate cancer characterization on MR images using fractal features / R Lopes, A Ayache, N Makni, et al. // Med Phys. – 2011. – Vol. 38(1). –P.83–95. Doi: 10.1118/1.3521470.
23. Quantitative monitoring of gene expression patterns with a complementary DNA microarray / M Schena, D Shalon, RW Davis, et al. - Science. – 1995. – Vol.270(5235). –P.467–470. Doi: 10.1126/science.270.5235.467.
24. Quantitative radiomics studies for tissue characterization:a review of technology and methodological procedures / R.T.H.M. Larue, G Defraene, D De Ruysscher, et al. // Br. J.Radiol. - 2017. - Vol. 90. - P. 125-138. Doi: 10.1259/bjr.20160665.
25. Radiomics: extracting more information from medical images using advanced feature analysis / P Lambin, E Rios-Velazquez, R Leijenaar, et al. // Eur J Cancer. - 2012. – Vol.48(4). – P.441–446. Doi: 10.1016/j.ejca.2011.11.036.
26. Radiomics and radiogenomics of prostate cancer / C Smith, P., M Czarniecki, S Mehralivand, et al // Abdominal Radiology. - 2019. – Vol. 44(6). – P.2021-2029. Doi:10.1007/s00261-018-1660-7.
27. Radiomics and radiogenomics for precision radiotherapy / J Wu, KK Tha, L Xing, et al. // J Radiat Res. - 2018. – Vol.59(1). – P.25–31. Doi: 10.1093/jrr/rrx102.
28. Radiomics and radiogenomics in lung cancer: A review for the clinician / R Thawani, M McLane, N Beig, et al. // Lung Cancer. – 2018. – Vol.115. – P.34–41. Doi: 10.1016/j.lungcan.2017.10.015.
29. Radiomics: the process and the challenges / V Kumar, Y Gu, S Basu, et al. // Magn Reson Imaging. – 2012. – Vol. 30(9). – P.1234–1248. Doi: 10.1016/j.mri.2012.06.010.
30. Robust prostate segmentation using intrinsic properties of TRUS images / P Wu, Y Liu, Y Li, et al. // IEEE Trans Med Imaging. – 2015. – Vol. 34(6). – P.1321–1335. Doi: 10.1109/TMI.2015.2388699
31. Rutman, A.M. Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging / A.M Rutman, M.D Kuo // Eur J Radiol. – 2009. – Vol.70(2). –P.232–241. Doi: 10.1016/j.ejrad.2009.01.050.
32. Spatial genomic heterogeneity within localized, multifocal prostate cancer / PC Boutros, M Fraser, NJ Harding, et al. // Nat Genet. – 2015. – Vol. 47(7). – P.736–745. Doi: 10.1038/ng.3315.
33. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands / DE Goldgar, DF Easton, LA Cannon-Albright, et al // J Natl Cancer Inst. - 1994. – Vol.86. - P: 1600–1608. Doi: 10.1093/jnci/86.21.1600.
34. The genetic epidemiology of prostate cancer and its clinical implications / R Eeles, C Goh, E Castro, et al // Nat Rev Urol. - 2014. – Vol. 11. – P. 18–31. Doi: 10.1038/nrurol.2013.266.
35. The Cancer Genome Atlas Research Network, 2015, https://www.genome.gov/Funded-Programs-Projects/Cancer-Genome-Atlas.
36. U.S. Cancer Statistics Working Group. US cancer statistics: 1999–2009 incidence and mortality webbased report. Atlanta GA: USDHHS, CDC; 2013. http://www.cdc.gov/uscs.
37. World Health Organization. Global Health Observatory data repository. http://apps.who.int/gho/data/view.main.SDG2016LEXREGv?lang=en, accessed [1st July 2017].
38. Zonal segmentation of prostate using multispectral magnetic resonance images / N Makni, A Iancu, O Colot, et al. // Med Phys. - 2011. – Vol. 38(11). – P.6093–6105. Doi: 10.1118/1.3651610.
Review
For citations:
Loginova M.V., Pavlov V.N., Gilyazova I.R. Radiomics and radiogenomics of prostate cancer. Yakut Medical Journal. 2021;(1):101-104. https://doi.org/10.25789/YMJ.2021.73.27
Views:
17
Email this article 